Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways
Abstract Cabazitaxel (CBZ) is approved for the treatment of docetaxel-resistant castration-resistant prostate cancer (CRPC). However, its efficacy against CRPC is limited, and there are no effective treatments for CBZ-resistant CRPC. This study explored the optimal treatment for CRPC in the post-cab...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/56f8f480566741bda2848c462abb3516 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|